Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate

A method of treating cancer in a subject, the method comprising administering to the subject an antibody or an antigen-binding fragment thereof, wherein the antibody binds to Programmed Death-1 (PD-1) and inhibits PD-1 activity, and an antibody-drug conjugate that binds to tissue factor (TF), wherein the antibody-drug conjugate comprises an anti-TF antibody or an antigen-binding fragment thereof conjugated to monomethyl auristatin E, wherein the anti-PD-1 antibody or antigen-binding fragment thereof comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises:

• (i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:17;
• (ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO:18;
• and
• (iii) a CDR-H3 comprising the amino acid sequence of SEQ ID NO:19;
• and
• wherein the light chain variable region comprises:
• (i) a CDR-L1 comprising the amino acid sequence of SEQ ID NO:20;
• (ii) a CDR-L2 comprising the amino acid sequence of SEQ ID NO:21;
• and
• (iii) a CDR-L3 comprising the amino acid sequence of SEQ ID NO:22,
• and wherein the anti-TF antibody or antigen-binding fragment thereof comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises:
• (i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:1;
• (ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO:2;
• and
• (iii) a CDR-H3 comprising the amino acid sequence of SEQ ID NO:3;
• and
• wherein the light chain variable region comprises:
• (i) a CDR-L1 comprising the amino acid sequence of SEQ ID NO:4;
• (ii) a CDR-L2 comprising the amino acid sequence of SEQ ID NO:5;
• and
• (iii) a CDR-L3 comprising the amino acid sequence of SEQ ID NO:6.